Moneycontrol
HomeNewsBusinessA year into business, Indian-American remote working startup valued at $600 million

A year into business, Indian-American remote working startup valued at $600 million

Document collaboration firm Coda on August 11 raised $80 million in a funding round led by Kleiner Perkins, a Silicon Valley marquee venture capital fund.

August 12, 2020 / 12:38 IST
Story continues below Advertisement

Startups in the remote working space raising money quickly and at high valuations seem to be the new normal as a coronavirus-hit world embraces work from home.

On August 11, document collaboration startup Coda said it raised $80 million in a funding round led by Kleiner Perkins, one of Silicon Valley’s oldest and marquee venture capital funds, valuing it at $636 million. Its other investors—Khosla Ventures, Greylock and General Catalyst— also participated in the round.

Story continues below Advertisement

The San Francisco-based startup was launched in 2019. CEO and co-founder Shishir Mehrotra previously held senior roles at Microsoft and YouTube alongside co-founder and college friend Alex DeNeui. Mehrotra was born and raised in the US, his LinkedIn profile says.

The pair started Coda in 2014 to reimagine online documentation— rather than have separate platforms for spreadsheets, documents, presentations and to-do lists, the startup would offer a blank slate where all could be created in one place. Coda could then transform the results into a web application without the need for any code, Forbes reported.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show